239483-09-1

Basic information

• Product Name: (S)-2-(AMINOETHYL)-1-N-BOC-PYRROLIDINE
• Synonyms: (S)-tert-butyl 2-(2-aminoethyl)pyrrolidine-1-carboxylate;tert-butyl (2S)-2-(2-aMinoethyl)pyrrolidine-1-carboxylate;2-Ethyl-pyrrolidine-1-carboxylic acid tert-butyl ester;tert-Butyl (2S)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate;1-Pyrrolidinecarboxylic acid, 2-(2-aminoethyl)-, 1,1-dimethylethyl ester, (2S)-;(S)-2-(Aminoethyl)-1-Boc-pyrrolidine
• CAS NO: 239483-09-1
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.307
• Mol File: 239483-09-1.mol

Chemical Properties

• Boiling Point: 297.5 °C at 760 mmHg
• Flash Point: 133.7 °C
• Appearance: /
• Density: 1.029
• Vapor Pressure: 0.00135mmHg at 25°C
• Refractive Index: 1.485
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.27±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(AMINOETHYL)-1-N-BOC-PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(AMINOETHYL)-1-N-BOC-PYRROLIDINE(239483-09-1)
• EPA Substance Registry System: (S)-2-(AMINOETHYL)-1-N-BOC-PYRROLIDINE(239483-09-1)

Safety Data

• RIDADR: UN3077
• Hazardous Substances Data: 239483-09-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-2-(AMINOETHYL)-1-N-BOC-PYRROLIDINE is used as a key intermediate for the synthesis of various chemical compounds. Its Boc-protected amino group allows for controlled reactions, enabling the formation of complex molecules with specific functionalities.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (S)-2-(AMINOETHYL)-1-N-BOC-PYRROLIDINE is utilized as a building block for the development of bioactive compounds. Its unique structure and Boc protection make it suitable for the creation of pharmaceuticals with targeted therapeutic effects.
Used in Pharmaceutical Industry:
(S)-2-(AMINOETHYL)-1-N-BOC-PYRROLIDINE is used as a precursor in the synthesis of pharmaceuticals for various therapeutic applications. Its versatility and the ability to protect the amino group during synthesis contribute to the development of innovative drug candidates with improved efficacy and safety profiles.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13-8-4-5-9(13)6-7-12/h9H,4-8,12H2,1-3H3/t9-/m0/s1

Upstream product

• 198493-30-0 tert-butyl (2S)-2-(2-oxoethyl)pyrrolidine-1-carboxylate 
• 69610-41-9 Boc-L-Pro-H 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 142253-50-7 (S)-2-cyanomethylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 86661-32-7 (S)-tert-butyl 2-((tosyloxy)methyl)pyrrolidine-1-carboxylate 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 

Downstream Products

• 1309563-52-7 (3aS,13aS)-N-[(2,4-difluorophenyl)methyl]-7,9-dioxo-8-[(phenylmethyl)oxy]-1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidine-10-carboxamide 
• 681247-79-0 tert-butyl (2S)-2-(2-{[(benzyloxy)carbonyl]amino}ethyl)-1-pyrrolidinecarboxylate 
• 160115-25-3 (S)-2-(2-Dimethylamino-ethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

D -Prolyl-2-(trifluoromethylsulfonamidopropyl)pyrrolidine: An Organocatalyst for Asymmetric Michael Addition of Aldehydes to β-Nitroalkenes at Ambient Conditions

Four 2-(trifluoromethylsulfonamidoalkyl)pyrrolidines and their d-prolinamides were prepared and screened as organocatalysts for the Michael addition reaction of aldehydes with β-nitroalkenes at rt and without the use of additives. d-Prolyl-2-(trifluoromet

Amino/guanidino-functionalized N-(pyrrolidin-2-ethyl)glycine-based pet-PNA: Design, synthesis and binding with DNA/RNA

The N-(pyrrolidin-2-ethyl) glycine-based PNA (pet-PNA) backbone, with 4-amino or 4-guanidino-functionalized pyrrolidine ring, confers constrained conformational flexibility on aegPNA. The oligomers bind to the target DNA and RNA sequences with increased sequence specificity and antiparallel versus parallel orientation selectivity. The easy post-synthetic guanidination gives very good access to the positively charged PNA oligomers.

POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

The present invention is to provide a novel compound (I), having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. Compound (I) wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.

Sulfonamides having antiangiogenic and anticancer activity

Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

HISTAMINE H3 RECEPTOR LIGANDS

Compounds of formula (I) (and pharmaceutically acceptable salts thereof) are histamine H3 receptor ligands. A in the formula represents (CH2)m, m being from 1 to 3; B is (CH2)n, n being from 1 to 3; x is from 0 to 2; Ris C1 to C10 hydrocarbyl, in which up to 2 carbon atoms may be replaced by O, S or N; and up to 2 hydrogen atoms may be replaced by halogen; Ris H or C1 to C15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen; Ris absent when -Y-Z-R2 is attached to W, or is H or C1 to C7 hydrocarbyl when -Y-Z-Ris not attached to W; W is nitrogen; X is -CH2-, -O- or -NR-, Rbeing H or C1 to C3 alkyl; Y replaces a hydrogen atom on any of A, B, W and X, and is C2 to C10 alkylene, in which one non-terminal carbon atom may be replaced by O; and Z is (II), (III), (IV), (V), (VI), or (VII) wherein R, Rand Rare independently H or C1 to C15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or methyl, or Q is linked to Ror Rto form a five-membered ring or Q is linked to Rto form a six-membered ring

INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2

Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

An enantioselective michael addition of soft nucleophiles to prochiral enone catalyzed by (2-Pyrrolidyl)alkyl ammonium hydroxide

(S)-N-(2-Pyrrolidylmethyl)-N,N,N-trimethylammonium hydoxide catalyzes the asymmetric Michael addition of soft nucleophiles to enones with moderate to high enantiomeric excess through ion-pair rather than steric control.